Grupo Almirall
Spain · ES0157097017 · reports in EUR · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +12% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 3.1% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 64% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €863M | €895M | €986M | €1.1B |
| Operating profit | €47M | −€5M | €36M | €73M |
| Net profit to shareholders | €4M | −€38M | €10M | €46M |
| Earnings per share | €0.02 | −€0.18 | €0.05 | €0.22 |
| Dividend per share | €0.19 | n/a | n/a | €0.19 |
| Cash from operations | €155M | €93M | €161M | €174M |
| Capital spending | €23M | €33M | €30M | €35M |
| Cash | €249M | €388M | €377M | €338M |
| Total assets | €2.1B | €2.4B | €2.4B | €2.3B |
| Equity | €1.3B | €1.5B | €1.5B | €1.5B |
What they do
In the company's own words, from the annual report.
la compra, fabricación, almacenamiento, comercialización y mediación en la venta de especialidades y productos farmacéuticos y de todo tipo de materias primas empleadas en la elaboración de dichas especialidades y productos farmacéuticos. Asimismo, el objeto social de la Sociedad Dominante también incluye: - La compra, fabricación, almacenamiento, comercialización y mediación en la venta de cosméticos, productos químicos, biotecnológicos y de diagnóstico para uso humano, veterinario, agroquímico y alimenticio, así como de toda clase de utensilios, complementos y accesorios para la industria química, farmacéutica y clínica. - La investigación de principios y productos químicos y farmacéuticos. - La compra, venta, alquileres, parcelación y urbanización de solares, terrenos y fincas de cualquier naturaleza, pudiendo proceder a la edificación de éstos y a su enajenación, íntegramente, en for
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.